There are few effective pharmacological treatments for Tourette’s syndrome. Many patients with Tourette’s syndrome experience impairing tic symptoms despite use of available evidence-based treatments.
The Yale University conducted a small study to examine the safety, tolerability, and dosing of THX-110, a combination of THC palmitoylethanolamide (PEA), in Tourette’s syndrome.
The findings have since been published on 3rd Aug 2021 by The Journal of Neuropsychiatry and Clinical Neurosciences.
Conducted at Yale’s department of psychiatry and child study centre, the trial evaluated SCI-110’s impact on tic severity in 16 adults using the Yale Global Tic Severity Scale (YGTSS). It found a significant improvement in tic symptoms over time, with a 7-point decrease in YGTSS score or an average improvement of more than 20%.
Based on the study results, SciSparc have arrange further research with a randomised, double-blind placebo-controlled trial to evaluate the safety, tolerability and efficacy of daily oral SCI-110 in treating adults with Tourette Syndrome.